Lilly Asia Ventures

Heyuan Medical Devices serves as an enterprise service provider, offering specialized medical equipment and support solutions tailored to the needs of healthcare institutions and organizations

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Fine Vision is a company with R&D facilities in Nanjing and Wuhan that focuses on femtosecond laser application research in the fields of ocular surgery and biomaterial processing. The entire femtosecond laser corneal refractive surgery equipment, its first commercially available item, was developed by the university's Wuhan Optoelectronics National Research Center under the Huazhong Technology Technology transition.

Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment.

Targeting One is a joint-stock technology firm that creates reagents, software, and other products. It is committed to developing products in the life science and molecular diagnostic enterprise, serving life science, precision medicine, drug development, and health management, by developing molecular diagnostic technologies with multiple indicators, high throughput, automation, pollution prevention, and relatively inexpensive.

Akura Medical is focused on developing innovative medical devices aimed at improving the process of thrombectomy, specifically through a next-generation device designed for easy use in a single-pass procedure to efficiently remove blood clots. The company specializes in thrombectomy devices and also offers a range of surgical, medical, dental, and veterinary instruments. By providing effective solutions for clot removal, Akura Medical enables healthcare professionals to better address critical needs and treat venous thromboembolism of varying sizes.

Ronovo Surgical is an emerging medical technology company dedicated to innovating minimally invasive and digital surgery. The company has developed a soft tissue surgery robot platform that utilizes advanced robotics and digital solutions to enhance surgical procedures. This platform aims to improve efficiency and precision across various surgical specialties, ultimately optimizing patient outcomes and health economics. By focusing on these innovations, Ronovo Surgical seeks to disrupt traditional surgical care in China and address the evolving needs of the medical industry.

Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.

Ronovo Surgical is an emerging medical technology company dedicated to innovating minimally invasive and digital surgery. The company has developed a soft tissue surgery robot platform that utilizes advanced robotics and digital solutions to enhance surgical procedures. This platform aims to improve efficiency and precision across various surgical specialties, ultimately optimizing patient outcomes and health economics. By focusing on these innovations, Ronovo Surgical seeks to disrupt traditional surgical care in China and address the evolving needs of the medical industry.

LavaMed is a China based medical devices manufacturing company.

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.

Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.

ForQaly specializes in the development of minimally invasive ventricular assist devices designed to treat heart failure patients. The company focuses on creating therapeutic devices that enhance circulation while ensuring affordability for patients. Their products are characterized by features such as reduced trauma, high auxiliary flow, and user-friendly design, providing healthcare professionals with effective solutions for improving patient health. By combining innovation with accessibility, ForQaly aims to address the clinical needs of patients suffering from heart conditions.

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

Ronovo Surgical is an emerging medical technology company dedicated to innovating minimally invasive and digital surgery. The company has developed a soft tissue surgery robot platform that utilizes advanced robotics and digital solutions to enhance surgical procedures. This platform aims to improve efficiency and precision across various surgical specialties, ultimately optimizing patient outcomes and health economics. By focusing on these innovations, Ronovo Surgical seeks to disrupt traditional surgical care in China and address the evolving needs of the medical industry.

FutureGen is a biopharmaceutical company focused on developing innovative biologics in the fields of immunology and cancer. The company utilizes its advanced Structure-based Targeted Evolution Platform (STEP) to efficiently screen and produce high-quality antibodies aimed at discovering new drug treatments. By integrating various technologies, FutureGen aims to enhance the development of antibody drugs that provide improved therapies for cancer and related diseases. The company possesses expertise in medication development, clinical research, and quality control, positioning it to make significant contributions to the biopharmaceutical industry and improve patient outcomes.

Targeting One is a joint-stock technology firm that creates reagents, software, and other products. It is committed to developing products in the life science and molecular diagnostic enterprise, serving life science, precision medicine, drug development, and health management, by developing molecular diagnostic technologies with multiple indicators, high throughput, automation, pollution prevention, and relatively inexpensive.

MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for diverse applications, including wound care, dermatology, animal health, eye care, and oral care. Based in Woodstock, Georgia, and incorporated in 1999, the company offers over 100 commercially available products worldwide. Its key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for managing dermatoses; Celacyn gel for scar management; and SebuDerm for seborrhea relief. Additionally, Sonoma provides Acuicyn for eye care, Microcyn for expedited wound healing, and various products targeting animal health, such as MicrocynAH and MicrocynVS. The company's focus on addressing unmet medical needs in chronic skin conditions significantly contributes to enhancing patient care while aiming to reduce overall healthcare costs. Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. and rebranded in December 2016.

New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.

Legend Biotech is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cell therapies for oncology and other medical conditions. The company employs a variety of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell therapies and natural killer cell-based immunotherapy. Its leading product candidate, LCAR-B38M/JNJ-4528, is designed as a chimeric antigen receptor T cell therapy specifically for treating multiple myeloma. Legend Biotech primarily generates its revenue through licensing and collaboration agreements, with a significant portion coming from the United States.

Ronovo Surgical is an emerging medical technology company dedicated to innovating minimally invasive and digital surgery. The company has developed a soft tissue surgery robot platform that utilizes advanced robotics and digital solutions to enhance surgical procedures. This platform aims to improve efficiency and precision across various surgical specialties, ultimately optimizing patient outcomes and health economics. By focusing on these innovations, Ronovo Surgical seeks to disrupt traditional surgical care in China and address the evolving needs of the medical industry.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

“Peijia Medical” was established in early 2012, by returned oversea Chinese expert in professional medical device industry, providing R&D and production of interventional medical products. The company with register capital of RMB￥30 million is located in Suzhou Industrial Park, Suzhou city of Jiangsu Province. The city of Suzhou is famously named as "earthly paradise in China" and the Industrial Park beside Jinji Lake is called as “new paradise of venture capital investment”. The company covers an area of about 10000 sqm, within which laboratory and controlled environment room taking about 1800 sqm. The company has state of the art interior design with western high tech modern style infused with Suzhou oriental garden style. The office building, laboratory, and controlled environment production rooms are fully put into operation now.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

NuVera Medical, Inc. is a privately held company based in Campbell, California, specializing in the development of an innovative imaging platform designed for complex cardiovascular procedures. Established in 2016, the company utilizes advanced 4D ultrasound technology to enhance intracardiac echocardiography. This platform enables healthcare specialists, particularly cardiologists, to perform transcatheter cardiac interventions by providing real-time visualization of heart chambers. This capability supports informed decision-making during procedures, ultimately aiming to improve patient outcomes in cardiovascular care. NuVera Medical operates under the portfolio of Shifamed, LLC.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Sansure Biotech Inc. is a biotechnology company based in Changsha, Hunan Province, specializing in molecular diagnostics and genetic testing. Established in 2008, the company develops and sells a range of products, including nucleic acid extraction kits and real-time PCR diagnostic and research kits, as well as fluorescence systems. Its offerings include diagnostic kits for various diseases such as COVID-19, viral hepatitis, AIDS, cancer-related biomarkers, and respiratory tract infections, among others. Sansure Biotech serves hospitals and laboratories both in China and internationally, providing essential medical devices and laboratory equipment designed for accurate diagnoses and research in the field of molecular biology.

“Peijia Medical” was established in early 2012, by returned oversea Chinese expert in professional medical device industry, providing R&D and production of interventional medical products. The company with register capital of RMB￥30 million is located in Suzhou Industrial Park, Suzhou city of Jiangsu Province. The city of Suzhou is famously named as "earthly paradise in China" and the Industrial Park beside Jinji Lake is called as “new paradise of venture capital investment”. The company covers an area of about 10000 sqm, within which laboratory and controlled environment room taking about 1800 sqm. The company has state of the art interior design with western high tech modern style infused with Suzhou oriental garden style. The office building, laboratory, and controlled environment production rooms are fully put into operation now.

NuVera Medical, Inc. is a privately held company based in Campbell, California, specializing in the development of an innovative imaging platform designed for complex cardiovascular procedures. Established in 2016, the company utilizes advanced 4D ultrasound technology to enhance intracardiac echocardiography. This platform enables healthcare specialists, particularly cardiologists, to perform transcatheter cardiac interventions by providing real-time visualization of heart chambers. This capability supports informed decision-making during procedures, ultimately aiming to improve patient outcomes in cardiovascular care. NuVera Medical operates under the portfolio of Shifamed, LLC.

MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

Betta Pharmaceuticals Co., Ltd. is a prominent Chinese pharmaceutical company, established in 2003 and headquartered in Hangzhou. It specializes in the research, development, manufacturing, and marketing of innovative medicines aimed at treating malignant tumors, diabetes, and cardio-cerebrovascular diseases. Among its notable products is Icotinib hydrochloride, a reversible tyrosine kinase inhibitor used for non-small-cell lung cancer, which has garnered recognition for being the first targeted anti-cancer drug developed in China. Betta is actively engaged in over 20 new drug development projects and has formed strategic partnerships, including an agreement with Amgen Inc. for marketing Vectibix in China. The company prides itself on its independent intellectual property rights and has received numerous awards for its contributions to pharmaceutical innovation, including multiple national science and technology prizes. With a workforce nearing 1,000 employees, including a team of highly educated professionals, Betta Pharmaceuticals is dedicated to enhancing public health through the development of high-quality, affordable medications.